Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected
Patients on Tenofovir therapy: Relevance for Screening
Strategies

J 2019

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

WANDELER, Gilles; Etienne MAURON; Andrew ATKINSON; Jean-François DUFOUR; David KRAUS et. al.

Basic information

Original name

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

Authors

WANDELER, Gilles; Etienne MAURON; Andrew ATKINSON; Jean-François DUFOUR; David KRAUS (203 Czech Republic, belonging to the institution); Peter REISS; Lars PETERS; François DABIS; Jan FEHR; Enos BERNASCONI; Marc van der VALK; Colette SMIT; Lars K GJÆRDE; Jürgen ROCKSTROH; Didier NEAU; Fabrice BONNET and Andri RAUCH

Edition

Journal of Hepatology, Amsterdam, ELSEVIER SCIENCE BV, 2019, 0168-8278

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

Netherlands

Confidentiality degree

is not subject to a state or trade secret

References:

Full Text

Impact factor

Impact factor: 20.582

RIV identification code

RIV/00216224:14310/19:00109458

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1016/j.jhep.2019.03.032

UT WoS

000475462500010

EID Scopus

2-s2.0-85066398836

Keywords in English

Hepatitis B infection; HIV infection; Hepatocellular carcinoma; Screening; Antiretroviral; Nucleotide inhibitors; Surveillance

Abstract

V originále

Background and aims Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study. Methods We included all HIV-infected adults with a positive hepatitis B surface antigen followed in one of four prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors. Results 3,625 HIV/HBV-coinfected patients, of whom 72% have initiated TDF-containing ART were included. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% confidence interval [CI] 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10 years increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was above the commonly used screening threshold of 2 cases per 1,000 py only in patients aged >46 years at TDF initiation. Conclusions Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients initiating TDF without cirrhosis at an age <46 years. Lay summary: We investigated the incidence of hepatocellular carcinoma (HCC) in HIV/HBV-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed an HCC. The incidence of HCC remained low in patients initiating TDF without cirrhosis at an age <46 years.

Cite

WANDELER, Gilles; Etienne MAURON; Andrew ATKINSON; Jean-François DUFOUR; David KRAUS; Peter REISS; Lars PETERS; François DABIS; Jan FEHR; Enos BERNASCONI; Marc van der VALK; Colette SMIT; Lars K GJÆRDE; Jürgen ROCKSTROH; Didier NEAU; Fabrice BONNET and Andri RAUCH. Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies. Journal of Hepatology. Amsterdam: ELSEVIER SCIENCE BV, 2019, vol. 71, No 2, p. 274-280. ISSN 0168-8278. Available from: https://dx.doi.org/10.1016/j.jhep.2019.03.032.

@article{1521336,
   author = {Wandeler, Gilles and Mauron, Etienne and Atkinson, Andrew and Dufour, JeanandFrançois and Kraus, David and Reiss, Peter and Peters, Lars and Dabis, François and Fehr, Jan and Bernasconi, Enos and Valk, Marc van der and Smit, Colette and Gjærde, Lars K and Rockstroh, Jürgen and Neau, Didier and Bonnet, Fabrice and Rauch, Andri},
   article_location = {Amsterdam},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.jhep.2019.03.032},
   keywords = {Hepatitis B infection; HIV infection; Hepatocellular carcinoma; Screening; Antiretroviral; Nucleotide inhibitors; Surveillance},
   language = {eng},
   issn = {0168-8278},
   journal = {Journal of Hepatology},
   title = {Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies},
   url = {https://www.sciencedirect.com/science/article/pii/S0168827819302260},
   volume = {71},
   year = {2019}
}

TY  - JOUR
ID  - 1521336
AU  - Wandeler, Gilles - Mauron, Etienne - Atkinson, Andrew - Dufour, Jean-François - Kraus, David - Reiss, Peter - Peters, Lars - Dabis, François - Fehr, Jan - Bernasconi, Enos - Valk, Marc van der - Smit, Colette - Gjærde, Lars K - Rockstroh, Jürgen - Neau, Didier - Bonnet, Fabrice - Rauch, Andri
PY  - 2019
TI  - Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies
JF  - Journal of Hepatology
VL  - 71
IS  - 2
SP  - 274-280
EP  - 274-280
PB  - ELSEVIER SCIENCE BV
SN  - 01688278
KW  - Hepatitis B infection
KW  - HIV infection
KW  - Hepatocellular carcinoma
KW  - Screening
KW  - Antiretroviral
KW  - Nucleotide inhibitors
KW  - Surveillance
UR  - https://www.sciencedirect.com/science/article/pii/S0168827819302260
L2  - https://www.sciencedirect.com/science/article/pii/S0168827819302260
N2  - Background and aims Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study. Methods We included all HIV-infected adults with a positive hepatitis B surface antigen followed in one of four prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors. Results 3,625 HIV/HBV-coinfected patients, of whom 72% have initiated TDF-containing ART were included. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% confidence interval [CI] 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10 years increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was above the commonly used screening threshold of 2 cases per 1,000 py only in patients aged >46 years at TDF initiation. Conclusions Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients initiating TDF without cirrhosis at an age <46 years. Lay summary: We investigated the incidence of hepatocellular carcinoma (HCC) in HIV/HBV-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed an HCC. The incidence of HCC remained low in patients initiating TDF without cirrhosis at an age <46 years.
ER  -

WANDELER, Gilles; Etienne MAURON; Andrew ATKINSON; Jean-Fran$\backslash$c cois DUFOUR; David KRAUS; Peter REISS; Lars PETERS; Fran$\backslash$c cois DABIS; Jan FEHR; Enos BERNASCONI; Marc van der VALK; Colette SMIT; Lars K GJÆRDE; Jürgen ROCKSTROH; Didier NEAU; Fabrice BONNET and Andri RAUCH. Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies. \textit{Journal of Hepatology}. Amsterdam: ELSEVIER SCIENCE BV, 2019, vol.~71, No~2, p.~274-280. ISSN~0168-8278. Available from: https://dx.doi.org/10.1016/j.jhep.2019.03.032.

Přehled o publikaci